basiliximab (Simulect)

Monoclonal antibody

Approved / Phase 4IL-2 receptor alpha (IL2RA)No featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Kidney Transplant Rejection Prophylaxis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
EU
  • Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
Product first approved 1998EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Other / comorbidity
NCT00468117 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-01 – 2017-07-05 · Type 1 Diabetes Mellitus
What this study did
NCT01843348 · Novartis Pharmaceuticals
2012-12-27 – 2016-03-23 · Kidney Transplantation, Renal Transplantation
What this study did
NCT00434811 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-10 – 2014-05 · Type 1 Diabetes Mellitus
What this study did
NCT01011205 · Astellas Pharma Inc
2009-09-30 – 2013-01-04 · Liver Transplantation
What this study did
NCT00378014 · Novartis Pharmaceuticals
2006-08 – 2013-01 · Liver Transplantation
What this study did
NCT00251004 · Novartis
2005-10 – 2009-10 · Kidney Transplantation, Graft Rejection
What this study did
NCT00154284 · Novartis
2005-07 – 2008-07 · Organ Transplantation, Renal Transplantation
What this study did
NCT00302497 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2007-04 – 2008-04 · Kidney Transplant
What this study did
NCT00188825 · University Health Network, Toronto
2004-05 – 2007-10 · COPD, Emphysema, Alpha-1 Antitrypsan Deficiency
What this study did
NCT00238901 · Novartis
2002-12 – 2005-07 · Liver Transplant
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT00729768 · Genentech, Inc.
— · Kidney Transplantation
What this study did
NCT00928811 · Drexel University College of Medicine
2009-05 – 2010-04 · End Stage Renal Disease
What this study did
Phase 2 (28)
Other / comorbidity
NCT04871607 · City of Hope Medical Center
2021-11-02 – 2029-10-02 · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT06480630 · Anhui Provincial Hospital
2024-07-01 – 2027-06-30 · Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
What this study did
NCT04337593 · Beijing Tongren Hospital
2020-06-01 – 2022-12-31 · Extranodal NK/T-cell Lymphoma
What this study did
NCT05013034 · Fort Worth Clinical Sciences Working Group
2021-10-15 – 2022-12-01 · SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm
What this study did
NCT02464878 · Massachusetts General Hospital
2017-01 – 2022-12 · Kidney Transplant, Type 1 Diabetes
What this study did
NCT03663335 · Novartis Pharmaceuticals
2018-11-28 – 2021-10-29 · Kidney Transplantation
What this study did
NCT02921789 · Astellas Pharma Global Development, Inc.
2017-05-22 – 2021-05-18 · Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
What this study did
NCT02366728 · Mustafa Khasraw, MBChB, MD, FRCP, FRACP
2015-10-12 – 2020-10-31 · Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
What this study did
NCT03192657 · RenJi Hospital
2017-07 – 2020-06 · Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis
What this study did
NCT01780844 · Astellas Pharma Global Development, Inc.
2013-03-05 – 2017-01-27 · Kidney Transplantation
What this study did
NCT01485055 · Nationwide Children's Hospital
2011-12 – 2016-09-26 · Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
What this study did
NCT01856257 · National Institute of Allergy and Infectious Diseases (NIAID)
2013-07 – 2016-04 · Primary Renal Allograft Candidate, Kidney Transplantation
What this study did
NCT01884571 · Emory University
2013-10 – 2016-01 · Amyotrophic Lateral Sclerosis (ALS)
What this study did
NCT01436305 · National Institute of Allergy and Infectious Diseases (NIAID)
2011-09 – 2015-04 · Kidney Transplantation, Renal Transplantation
What this study did
NCT00789308 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-07-11 – 2014-08-21 · Diabetes Mellitus, Type I
What this study did
NCT00464555 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-12 – 2014-02 · Type 1 Diabetes Mellitus
What this study did
NCT00434850 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-10 – 2013-11 · Diabetes Mellitus, Type 1
What this study did
NCT00975975 · Indiana University
2009-09 – 2013-11 · Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
What this study did
NCT00468403 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-10 – 2013-04 · Type 1 Diabetes Mellitus
What this study did
NCT00890253 · Armin Goralczyk
2010-01 – 2013-01 · Liver Transplantation, Chronic Renal Insufficiency
What this study did
NCT00555321 · Bristol-Myers Squibb
2008-01 – 2011-06 · Immunosuppression in Solid Organ Transplant
What this study did
NCT00790439 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-07 – 2009-10 · Diabetes Mellitus, Type I
What this study did
NCT01061996 · Cerimon Pharmaceuticals
2007-07 – 2008-12 · Ulcerative Colitis
What this study did
NCT00646425 · Cerimon Pharmaceuticals
2008-05 – 2008-11 · Non-infectious Uveitis
What this study did
NCT00430898 · Cerimon Pharmaceuticals
2007-01 – 2008-09 · Ulcerative Colitis
What this study did
NCT00409656 · University Hospital Freiburg
2003-12 – 2005-12 · Corneal Transplantation
What this study did
NCT00023244 · National Institute of Allergy and Infectious Diseases (NIAID)
2001-01 – 2005-06 · End-Stage Renal Disease
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT02561767 · First Affiliated Hospital, Sun Yat-Sen University
2015-10 – 2017-10 · Kidney Transplantation, Acute Kidney Tubular Necrosis
What this study did
NCT00752479 · Mario Negri Institute for Pharmacological Research
2008-05 – 2013-12 · Kidney Transplant
What this study did
Phase 1 (6)
Other / comorbidity
NCT05139004 · City of Hope Medical Center
2022-07-19 – 2027-06-13 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
What this study did
NCT02342782 · City of Hope Medical Center
2020-06-08 – 2024-11-18 · Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
What this study did
NCT01526096 · University of Chicago
2011-07-12 – 2024-08-28 · Myeloma
What this study did
NCT01476839 · City of Hope Medical Center
2013-02-13 – 2024-05-31 · Recurrent Adult Hodgkin Lymphoma
What this study did
NCT01842139 · University of Chicago
2011-12-05 – 2018-03 · Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
What this study did
NCT00626483 · Gary Archer Ph.D.
2007-04-24 – 2016-07-06 · Malignant Neoplasms Brain
What this study did
Phase 4 (27)
Kidney Transplant Rejection Prophylaxis
NCT03789006 · University of Khartoum
2018-03-21 – 2024-03-21 · Kidney Transplant Rejection
What this study did
NCT04773392 · University of Southern California
2021-11-23 – 2024-02-23 · Kidney Transplantation, Kidney Transplant Rejection
What this study did
Other / comorbidity
NCT06066840 · The First Affiliated Hospital of Soochow University
2022-08-01 – 2025-12-31 · Safety and Efficacy
What this study did
NCT04404127 · King Faisal Specialist Hospital & Research Center
2020-09-01 – 2025-05 · Kidney Transplantation
What this study did
NCT04104438 · Fady M Kaldas, M.D., F.A.C.S.
2021-01-15 – 2024-09-30 · Asses Immunosuppression Modulation on Renal Recovery Post LT
What this study did
NCT03794492 · Chong Kun Dang Pharmaceutical
2018-03-31 – 2023-04-27 · Kidney Transplant
What this study did
NCT05021276 · The First Affiliated Hospital of Soochow University
2020-12-15 – 2022-12-15 · Safety and Efficacy
What this study did
NCT02342145 · Zhongming Zhang
2015-04 – 2022-08-20 · Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)
What this study did
NCT03171831 · First Affiliated Hospital of Guangxi Medical University
2017-04-01 – 2022-04-01 · Thalassemia Major
What this study did
NCT02083991 · Vastra Gotaland Region
2013-01 – 2017-12 · Diabetes Mellitus
What this study did
NCT02377193 · University Hospital, Toulouse
2013-09 – 2017-01 · Renal Transplant Rejection
What this study did
NCT01560572 · University Medical Center Groningen
2011-04 – 2016-04 · Renal Insufficiency, Kidney Transplantation
What this study did
NCT02683291 · Associação Médico Espírita de Botucatu
2014-01 – 2016-01 · Disorder Related to Renal Transplantation, Cytomegalovirus Infections
What this study did
NCT02123108 · University of California, Los Angeles
2011-01 – 2015-01 · Liver Transplantation
What this study did
NCT00724022 · University Hospital Freiburg
2008-06 – 2014-07 · Disorder Related to Renal Transplantation
What this study did
NCT01817322 · Samsung Medical Center
2011-06 – 2013-08 · Chronic Renal Disease
What this study did
NCT00965094 · Novartis Pharmaceuticals
2009-12 – 2013-06 · Chronic Renal Failure
What this study did
NCT01304836 · Astellas Pharma Inc
2011-01-22 – 2013-05-22 · Kidney Transplantation
What this study did
NCT00634920 · Novartis Pharmaceuticals
2008-03 – 2013-05 · Renal Function
What this study did
NCT00956293 · Novartis Pharmaceuticals
2009-07 – 2013-03 · Renal Transplantation
What this study did
NCT00717470 · Astellas Pharma Inc
2008-05-14 – 2010-03-02 · Kidney Transplantation
What this study did
NCT00284947 · Novartis
2006-01 – 2008-12 · Kidney Transplantation, Adverse Effects
What this study did
NCT00296244 · Thomas Jefferson University
2006-02 – 2008-06 · Liver Cirrhosis, Liver Transplant Disorder
What this study did
NCT00149994 · Novartis Pharmaceuticals
2002-12 – 2007-12 · Liver Transplant
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT02459977 · Asan Medical Center
2012-04 – 2015-06 · Kidney Transplantation
What this study did
NCT01387659 · The University of Texas Medical Branch, Galveston
2011-03 – 2012-10 · Diabetes, Immunosuppression
What this study did
NCT00563108 · Hospital Authority, Hong Kong
2004-06 – 2008-12 · Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
What this study did
NCT00594308 · Indiana University
2007-10 – 2008-10 · Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Other / comorbidity
NCT05385432 · University Hospital, Tours
2023-11-07 – 2030-12-30 · Renal Transplant Rejection, Induction Therapy
What this study did
NCT01239563 · University of Oxford
2011-01 – 2016-05 · Kidney Transplantation, Ischemia-Reperfusion Injury
What this study did
NCT00514514 · Novartis Pharmaceuticals
2007-07 – 2015-06 · Kidney Transplantation
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT01120028 · University of Oxford
2010-09 – 2020-03 · Kidney Transplantation
What this study did
Phase 2 (2)
Other / comorbidity
NCT00543569 · Astellas Pharma Inc
2008-02 – 2011-02 · Kidney Transplantation
What this study did
NCT00235300 · Genzyme, a Sanofi Company
2000-05 – 2005-06 · Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT02492308 · Fuzhou General Hospital
2014-12 – 2017-12 · Living-relative Kidney Transplantation
What this study did
NCT02492490 · Fuzhou General Hospital
2014-12 – 2016-11 · Uremia
What this study did
Phase 4 (4)
Kidney Transplant Rejection Prophylaxis
NCT03006419 · Coordinación de Investigación en Salud, Mexico
2016-12-01 – 2019-07-30 · Kidney Transplant Rejection, Kidney Transplant; Complications
What this study did
Other / comorbidity
NCT02523768 · Centre Hospitalier Universitaire de Saint Etienne
2011-01-08 – 2020-02-24 · Glomerulonephritis, IgAN
What this study did
NCT02056938 · Nantes University Hospital
2014-06 – 2017-02 · Kidney Transplantation
What this study did
NCT00113269 · Astellas Pharma Inc
2005-05 – 2009-03 · Kidney Transplantation
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT02723786 · GlaxoSmithKline
2016-08-27 – 2018-03-06 · Kidney Transplantation (Status Post)
What this study did

Competitive landscape

Other IL-2 receptor alpha (IL2RA) drugs

BLN-326. Compare all 2 IL-2 receptor alpha (IL2RA) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Kidney Transplant Rejection Prophylaxis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Basiliximab (Simulect): this drugApprovedMonoclonal antibodyIL-2 receptor alpha (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
TX200Phase 1/2Cell therapyHLA-A*02 (CAR-Treg)not yet gradedNo reviewed efficacy summary in this indication
BLN-326
Phase 1(overall)
Biologic (subtype unspecified)IL-2 receptor alpha (IL2RA)
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow basiliximab (Simulect) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 1Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-06-13 · NCT05139004 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 2Recurrent Hodgkin Lymphoma, Refractory Hodgkin LymphomaRecruiting
Est. primary completion 2029-10-02 · NCT04871607 · CT.gov ↗
What to watch

See the full readout calendar ↗